In the first ever disclosure for the subcutaneous formulation of Opdivo, the CheckMate -67T Phase 3 trial demonstrates activity in advanced or metastatic clear cell renal cell carcinoma Company plans ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from a post-hoc analysis of the phase 3 CheckMate -9ER trial demonstrating that CABOMETYX ® (cabozantinib) in ...
(RTTNews) - Biopharmaceutical company Bristol Myers Squibb Co. (BMY) said Wednesday that following a routine review of the CheckMate -548 Phase 3 trial by an independent data monitoring committee or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results